ORLANDO, Fla., Dec. 7, 2015 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and long-term safety ...

The protein is composed of a single molecule of recombinant factor IX covalently fused to the dimeric Fc domain of IgG 1. 15,17 With Fc fusion proteins, the neonatal Fc receptor and the endogenous IgG ...

A long-acting coagulation factor treatment of patients with hemophilia B is safe and effective for preventing bleeding events, according to an article published online December 4 and in the December ...

Hemophilia B causes a deficiency in factor IX, a protein necessary for blood clotting. Replacement factor IX therapy is the gold standard treatment, but novel and genetic therapies are showing promise ...

The projected cost reductions held both for patients switching from a different extended-half-life product and for patients switching from a standard-half-life product. Switching patients with ...

With "fivefold increase in half-life" and "no safety complications whatsoever," CSL Behring's long-acting fusion protein that links recombinant coagulation factor IX with recombinant albumin (rIX-FP) ...

Hemophilia B is a rare X-chromosome-linked bleeding disorder caused by mutations in the blood clotting factor IX that reduce its circulating levels in blood. A clinical trial led by experts at the ...

Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., submitted a biologics license application (BLA) to the FDA for IB1001, a recombinant Factor IX therapy for hemophilia B. If approved, IB1001 ...

The clinical diagnostic industry is on the verge of a recombinant protein revolution. Recombinants have been available for decades and have served some sectors of diagnostics quite well, but they have ...

Prophylactic factor replacement in patients with hemophilia B improves outcomes but requires frequent injections. A recombinant factor IX Fc fusion protein (rFIXFc) with a prolonged half-life was ...